SCHEMBL7589148

SCHEMBL7589148

N#Cc1c(C(N)=O)c2ccccn2c1-c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.48
MKNK1 Q9BUB5 6/20 0.43
KDM4E B2RXH2 2/20 0.42
GLA P06280 2/20 0.42
GAA P10253 2/20 0.42
RAD51 Q06609 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
IKBKB O14920 1/20 0.41
MKNK2 Q9HBH9 5/20 0.41
MAP2K3 P46734 1/20 0.40
CYP11B1 P15538 1/20 0.39
MAOA P21397 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
IDO1 P14902 1/20 0.38
TBXAS1 P24557 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7587012 0.83 MKNK1 (0.46) CYP11B2MKNK1KDM4ERAD51IKBKB
SCHEMBL7584938 0.83 CYP11B2 (0.47) CYP11B2MKNK1RAD51MKNK2MAP2K3
SCHEMBL7586428 0.82 CYP11B2 (0.57) CYP11B2KDM4EGLAGAARAD51
SCHEMBL7585453 0.76 CYP11B2 (0.53) CYP11B2KDM4EGLAGAARAD51
SCHEMBL7590158 0.76 CYP11B2 (0.56) CYP11B2KDM4EGLAGAARAD51
SCHEMBL7855338 0.74 CYP11B2 (0.48) CYP11B2MKNK1KDM4ERAD51MKNK2
SCHEMBL7954819 0.72 KDM4E (0.42) CYP11B2MKNK1KDM4EGLAGAA
SCHEMBL7586850 0.71 MAPT (0.52) CYP11B2KDM4ECYP11B1ALDH1A1IDO1
SCHEMBL7957240 0.71 MKNK1 (0.39) CYP11B2MKNK1KDM4EGLAGAA
Methane SCHEMBL7588227 0.71 MAPT (0.51) CYP11B2KDM4ECYP11B1ALDH1A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US claimed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP claimed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO claimed
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US disclosed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP disclosed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them TNF, IL2, ZC3HAV1 CYP11B2 139/4885MKNK1 4073/4885KDM4E 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.